NFKB1 and esophageal squamous cell carcinoma: Treatment with both Linsitinib and JSH‐23 exhibited increased efficacy of Linsitinib in Linsitinib‐resistant cells, indicating that targeting on both IGF‐1R and NF‐κB may generate a promising therapeutic effect on ESCC.